Allogeneic stem cell transplantation for relapsed primary central nervous system lymphoma: Is it feasible?

Erden Atilla; Ugur Sahin; Pinar Ataca Atilla; Mustafa Merter; Elif Ozyurek; Koray Ceyhan; Sinem Civriz Bozdag

doi:10.1016/j.hemonc.2018.02.001

Allogeneic stem cell transplantation for relapsed primary central nervous system lymphoma: Is it feasible?

Hematol Oncol Stem Cell Ther. 2019 Dec;12(4):220-225. doi: 10.1016/j.hemonc.2018.02.001. Epub 2018 Mar 16.

Authors

Erden Atilla¹, Ugur Sahin², Pinar Ataca Atilla², Mustafa Merter², Elif Ozyurek³, Koray Ceyhan⁴, Sinem Civriz Bozdag²

Affiliations

¹ Ankara University School of Medicine, Department of Hematology, Cebeci, Ankara, Turkey. Electronic address: erdenatilla@gmail.com.
² Ankara University School of Medicine, Department of Hematology, Cebeci, Ankara, Turkey.
³ Ankara University School of Medicine, Department of Radiology, Cebeci, Ankara, Turkey.
⁴ Ankara University School of Medicine, Department of Pathology, Sihhiye, Ankara, Turkey.

PMID: 29559300
DOI: 10.1016/j.hemonc.2018.02.001

Abstract

Primary central nervous system lymphoma (PCNSL), has an aggressive course and in untreated patients median survival is limited to three months. For relapsed PCNSL, the treatment options are few and results are usually unsatisfactory. Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT) has been widely used for treatment of relapsed/refractory NHL patients. However there are limited data whether graft versus lymphoma effect can work in PCNSL patients. Here, we present a relapsed refractory PCNSL case treated by allo-HCT.

Keywords: Allogeneic stem cell transplantation; Graft versus leukemia effect; Primary central nervous system lymphoma.

Publication types

Case Reports

MeSH terms

Adult
Brain Neoplasms / diagnostic imaging
Brain Neoplasms / therapy
Hematopoietic Stem Cell Transplantation*
Humans
Lymphoma, Non-Hodgkin* / diagnostic imaging
Lymphoma, Non-Hodgkin* / therapy
Male
Recurrence
Tomography, X-Ray Computed*
Transplantation, Homologous